Treating Advanced Solid Tumors with Targeted Therapies Called RAS(ON) Inhibitors Combined With the Targeted Immunotherapy Ivonescimab
Treatment
Phase 1/2 treatment study for solid tumors with a RAS mutation
Clinicaltrials.gov identifier:NCT07397338
Study Contact Information:
For additional information, contact:
Revolution Medicines Study Director
📞 1-844-2-REVMED
📧 [email protected]
About the Study
This study is testing whether combining a new type of targeted drug called RAS(ON) inhibitors with an drug called ivonescimab is safe and may help slow or shrink cancer in people with advanced or solid tumors that have a called a RAS mutation.
RAS(ON) inhibitors are oral targeted therapies designed to block a pathway called RAS, which plays a role in several types of cancer. RAS(ON) inhibitors are not yet FDA‑approved and are only available through participation in a clinical trial. One RAS(ON) inhibitor, known as daraxonrasib is available for people with advanced pancreatic cancer through a program known as . You can read more about for daraxonrasib.
Ivonescimab combines a type of called an with a type of known as a VEGF inhibitor that blocks the blood supply to tumors. Ivonescimab is not FDA-approved and is only available in the United States through participation in a clinical trial.
This Study is Open To:
In order to participate, people must have the following:
- Diagnosed with an advanced or solid tumor (such as lung or colorectal cancer).
- Their cancer must have a known as a RAS mutation (KRAS, NRAS, or HRAS).
- Their cancer can be seen and measured on scans.
- They are able to take oral medication.
- Good overall physical functioning.
Some parts of the study are for people who:
- Have already received standard treatments and their cancer progressed, or
- Have non‑squamous non‑small cell lung cancer with no other biomarkers with a option and have not yet received systemic treatment.
See clinicaltrials.gov for full eligibility criteria.
This Study is NOT Open To:
People with any of the following cannot join the study:
- Have head or neck squamous cell cancer.
- Have a medical condition that could interfere with taking or absorbing oral medications.
- Have had major surgery within the past 4 weeks.
What the Study Involves
Participants will receive one of the following RAS(ON) inhibitors to be taken orally (by mouth) daily:
- Daraxonrasib
- Elironrasib
- Zoldonrasib
Ivonescimab is given as an injection IV (into the vein).
Some participants may also receive additional cancer treatments, depending on their cancer type, such as:
- Platinum‑based chemotherapy with pemetrexed
- Cetuximab
Participants will receive the study drugs and remain on the study as long as the drugs are helping and side effects are manageable.
This is an open‑label study, meaning participants and researchers know which treatments are being given.
Study Contact Information:
For additional information, contact:
Revolution Medicines Study Director
📞 1-844-2-REVMED
📧 [email protected]
Locations:
Connecticut
City: Norwich RECRUITING
Facility: Eastern Connecticut Hematology and Oncology Associates
Contact Info:
[email protected]
860-886-8362
Tennessee
City: Nashville RECRUITING
Facility: Tennessee Oncology
Contact Info:
[email protected]
615-879-6410
Texas
City: Irving RECRUITING
Facility: NEXT Dallas
Contact Info:
[email protected]
972-893-8800
City: San Antonio RECRUITING
Facility: NEXT Oncology
Contact Info:
[email protected]
210-580-9521
Virginia
City: Fairfax RECRUITING
Facility: NEXT Virginia
Contact Info:
[email protected]
703-783-4518
Treatment
Phase 1/2 treatment study for solid tumors with a RAS mutation
Clinicaltrials.gov identifier:NCT07397338
Study Contact Information:
For additional information, contact:
Revolution Medicines Study Director
📞 1-844-2-REVMED
📧 [email protected]